2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.
Details
State: Public
Version: Final published version
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_EF7F13CAC757
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.
Journal
Annals of Oncology
Working group(s)
Panel Members
Contributor(s)
Stahel R., Felip E., Peters S., Kerr K., Besse B., Vansteenkiste J., Eberhardt W., Edelman M., Mok T., O'Byrne K., Novello S., Bubendorf L., Marchetti A., Baas P., Reck M., Syrigos K., Paz-Ares L., Smit EF., Meldgaard P., Adjei A., Nicolson M., Crinò L., Van Schil P., Senan S., Faivre-Finn C., Rocco G., Veronesi G., Douillard JY., Lim E., Dooms C., Weder W., De Ruysscher D., Le Pechoux C., De Leyn P., Westeel V.
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Publication state
Published
Issued date
2014
Volume
25
Number
8
Pages
1475-1484
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Abstract
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on first line/second and further lines of treatment in advanced disease.
Pubmed
Web of science
Open Access
Yes
Create date
19/09/2014 17:10
Last modification date
14/02/2022 7:57
Usage data
